塞力斯医疗科技集团股份有限公司（以下简称"公司"）2020 年 8 月 21 日 公开发行的可转换公司债券（以下简称"本期债券"）将于 2023 年 8 月 21 日支 付自 2022 年 8 月 21 日至 2023 年 8 月 20 日期间的利息。根据公司《公开发行可 转换公司债券募集说明书》（以下简称"《募集说明书》"）及《公开发行可转 换公司债券上市公告书》（以下简称"《上市公告书》"）有关条款的规定，现 将有关事项公告如下： | 证券代码：603716 | 证券简称：塞力医疗 | 公告编号：2023-087 | | --- | --- | --- | | 债券代码：113601 | 债券简称：塞力转债 | | 塞力斯医疗科技集团股份有限公司 关于可转换公司债券 2023 年付息公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示: | 债券名称 | 塞力斯医疗科技集团股份有限公司可转换公司债券 | | --- | --- | | 债券简称 | 塞力转债 | | 债券代码 | 113601 | | ...

关于塞力斯医疗科技集团股份有限公司 股票交易异常波动问询函的回复函 塞力斯医疗科技集团股份有限公司： 关于塞力斯医疗科技集团股份有限公司 股票交易异常波动问询函的回复函 塞力斯医疗科技集团股份有限公司: 本公司于 2023 年 8 月11日收到《塞力斯医疗科技集团股份有限公司关于股 票交易异常波动的问询函》，经认真自查,现就有关情况回复如下: 本人于 2023 年 8 月 11 日收到《塞力斯医疗科技集团股份有限公司关于股票 交易异常波动的问询函》，经认真自查，现就有关情况回复如下： 作为塞力斯医疗科技集团股份有限公司（以下简称"公司"）的实际控制人， 本人不存在影响公司股票价格异常波动的重大事项；不存在在本次股票交易异常 波动期间买卖公司股票的情况；不存在其他应披露而未披露的重大信息，包括但 不限于重大资产重组、股份发行、重大交易类事项、业务重组、股份回购、股权 激励、破产重整、重大业务合作、引进战略投资者等重大事项。 实际控制人： 2023 年 8 月 11 日 截至目前,作为塞力斯医疗科技集团股份有限公司(以下简称"公司")的 控股股东,本公司不存在影响公司股票价格异常波动的重大事项;不存在在本次 股票 ...

| 证券代码：603716 | 证券简称：塞力医疗 公告编号：2023-086 | | --- | --- | | 债券代码：113601 | 债券简称：塞力转债 | 塞力斯医疗科技集团股份有限公司 股票交易异常波动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 公司股票于 2023 年 8 月 10 日、8 月 11 日连续 2 个交易日内日收盘价格涨 幅偏离值累计超过 20%，根据《上海证券交易所交易规则》的有关规定，属于股 票交易异常波动的情形。 二、公司关注并核实的相关情况 重要内容提示： 塞力斯医疗科技集团股份有限公司（以下简称"公司"）股票交易连续2 个交易日（2023年8月10日、8月11日）收盘价格涨幅偏离值累计超过20%，根据 《上海证券交易所交易规则》的有关规定，属于股票交易异常波动情形。 （一）生产经营情况 经公司自查，并向控股股东赛海（上海）健康科技有限公司（以下简称 "赛海科技"）及实际控制人温伟先生发函核实，截至本公告披露日，控股股东 及实际控制人不存在应披露而未披露的重大信息，包括但不 ...

二、公司业绩亏损的风险 公司目前公司生产经营活动一切正常，市场环境、行业政策没有发生重大调 整，公司下属 SPD 及 IVD 业务、凝血相关生产试剂等生产研发正常开展，内部生 产经营秩序正常。 | 证券代码：603716 | 证券简称：塞力医疗 公告编号：2023-085 | | --- | --- | | 债券代码：113601 | 债券简称：塞力转债 | 塞力斯医疗科技集团股份有限公司 关于股票价格波动暨风险提示公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 塞力斯医疗科技集团股份有限公司（以下简称"公司"）股票于2023年8月7 日、8月8日、8月9日连续三个交易日收盘价格涨幅偏离值累计超过20%，根据《上 海证券交易所交易规则》的有关规定，属于股票交易异常波动情形。公司已于2023 年8月10日披露《股票交易异常波动公告》（公告编号：2023-084）。2023年8月 10日，公司股票再次涨停。鉴于近期公司股票价格波动较大，敬请广大投资者注 意投资风险，理性投资。现将相关风险提示如下： 一、二级市场交易风险 ...

| 证券代码：603716 | 证券简称：塞力医疗 公告编号：2023-084 | | --- | --- | | 债券代码：113601 | 债券简称：塞力转债 | 塞力斯医疗科技集团股份有限公司 股票交易异常波动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 塞力斯医疗科技集团股份有限公司（以下简称"公司"）股票交易连续3 个交易日（2023年8月7日、8月8日、8月9日）收盘价格涨幅偏离值累计超过20%， 根据《上海证券交易所交易规则》的有关规定，属于股票交易异常波动情形。 二、公司关注并核实的相关情况 针对本次股票交易异常波动情况，公司对有关事项进行核实，现将核实情况 说明如下： （一）生产经营情况 经公司自查，目前公司生产经营活动一切正常，市场环境、行业政策没有发 生重大调整，公司下属 SPD 及 IVD 业务、凝血相关生产试剂等生产研发正常开 展，内部生产经营秩序正常。不存在影响公司股票交易价格异常波动的重大事宜， 不存在应披露而未披露的重大信息。 （二）重大事项情况 经公司自查，并向控 ...

关于塞力斯医疗科技集团股份有限公司 股票交易异常波动问询函的回复函 塞力斯医疗科技集团股份有限公司： 实际控制人： 本公司于 2023 年 8 月 9 日收到《塞力斯医疗科技集团股份有限公司关于股 票交易异常波动的问询函》，经认真自查,现就有关情况回复如下: 截至目前,作为塞力斯医疗科技集团股份有限公司(以下简称"公司")的 控股股东,本公司不存在影响公司股票价格异常波动的重大事项;不存在在本次 股票交易异常波动期间买卖公司股票的情况;不存在其他应披露而未披露的重大 信息,包括但不限于重大资产重组、股份发行、重大交易类事项、业务重组、股 份回购、股权激励、破产重整、重大业务合作、引进战略投资者等重大事项。 2023 年 8 月 9 日 关于塞力斯医疗科技集团股份有限公司 股票交易异常波动问询函的回复函 塞力斯医疗科技集团股份有限公司: 本人于 2023 年 8 月 9 日收到《塞力斯医疗科技集团股份有限公司关于股票 交易异常波动的问询函》，经认真自查，现就有关情况回复如下： 作为塞力斯医疗科技集团股份有限公司（以下简称"公司"）的实际控制人， 本人不存在影响公司股票价格异常波动的重大事项；不存在在本次股票交易 ...

Group 1: Company Overview and Business Models - Seer Medical focuses on two main business models: Integrated IVD (In Vitro Diagnostics) and Integrated SPD (Supply Chain Management) [3][4] - Integrated IVD involves long-term contracts with medical institutions for providing diagnostic instruments and related services, while Integrated SPD expands to overall supply chain management for medical consumables [5][6] - In 2022, the revenue from Integrated IVD was approximately 1.041 billion CNY with a gross margin of 23.34%, while Integrated SPD generated around 688.85 million CNY with a gross margin of 9.96% [7] Group 2: Market Presence and Expansion Plans - The company collaborates with over 2,300 medical institutions across China, with more than 500 being medical institutions [9] - Future plans include expanding SPD services nationwide and establishing regional testing centers [10][11] - The company aims to increase its market share by developing multiple business models in the SPD sector, particularly in regions like Chongqing and Sichuan [25][28] Group 3: Financial Performance and Projections - In 2022, Seer Medical achieved a revenue of 690 million CNY, maintaining stability despite economic challenges [25] - The company has set a revenue target of 2.3 billion CNY for 2023, with significant contributions expected from various subsidiaries [28] - The accounts receivable as of the end of 2022 was 1.767 billion CNY, with a significant portion being recoverable [31] Group 4: Risks and Challenges - The company faces challenges with increasing accounts receivable and a rising debt-to-asset ratio, which reached 60% [30] - Management has implemented measures to improve cash flow and reduce bad debt risks, focusing on strengthening accounts receivable management [29][31] - The company emphasizes the importance of maintaining transparency and managing risks associated with its business operations [34]

| 证券代码：603716 | 证券简称：塞力医疗 公告编号：2023-057 | | --- | --- | | 债券代码：113601 | 债券简称：塞力转债 | 塞力斯医疗科技集团股份有限公司 关于召开 2022 年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： http://roadshow.sseinfo.com/），中国证券报·中证网 （https://www.cs.com.cn/roadshow/yjsmh/） 会议召开方式：上证路演中心视频直播和网络互动、中证网路演中心网络 互动 投资者可于 2023 年 5 月 15 日（星期一）至 5 月 19 日（星期五）16:00 前 登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 ir@thaly.net.cn 进行提问。公司将在说明会上对投资者普遍关注的问题进行 回答。 塞力斯医疗科技集团股份有限公司（以下简称"公司"）已于 2023 年 4 月 27 日发布公司 2022 年度报告，为便于广大投资者更全面深入 ...

Financial Performance - In Q1 2023, the company reported revenue of CNY 444.07 million, a decrease of 23.29% compared to the same period last year[5]. - The net profit attributable to shareholders was a loss of CNY 14.91 million, representing a decline of 170% year-on-year[5]. - The basic earnings per share were CNY -0.07, a decrease of 173.25% compared to the same period last year[5]. - In Q1 2023, the company reported a net loss of CNY 6,651,427.65, compared to a net profit of CNY 25,738,000.43 in Q1 2022, indicating a significant decline in profitability[28]. - The company’s total comprehensive loss for the period was CNY 7,511,690.31, compared to a comprehensive income of CNY 21,546,216.99 in the same quarter last year[28]. Revenue Breakdown - The IVD business revenue was CNY 296.80 million, accounting for 66.79% of total revenue, down 5.91 percentage points from the previous year[7]. - Total operating revenue for Q1 2023 was ¥444,069,353.53, a decrease of 23.3% compared to ¥578,884,225.92 in Q1 2022[26]. - The total revenue from operating activities was CNY 587,950,514.74, an increase from CNY 459,800,471.28 in the same period last year, reflecting a growth of approximately 27.8%[29]. Expenses and Costs - Total expenses increased by 3.81% year-on-year to CNY 108 million, primarily due to increased sales and management expenses[10]. - Total operating costs for Q1 2023 were ¥455,311,016.55, down 15.7% from ¥540,110,563.59 in Q1 2022[26]. - Research and development expenses for Q1 2023 amounted to ¥7,450,644.90, a decrease of 13.6% from ¥8,630,117.36 in Q1 2022[26]. Cash Flow and Liquidity - The company’s cash flow from operating activities was CNY 38.64 million, which is not comparable to the previous period[5]. - The company reported a net cash flow from operating activities increase due to higher sales receipts[19]. - The company experienced a net cash flow from operating activities of CNY 38,642,551.81, a recovery from a negative cash flow of CNY 117,248,727.93 in Q1 2022[30]. - The company’s cash and cash equivalents decreased to 270.29 million from 394.54 million year-over-year[22]. - The company’s cash and cash equivalents at the end of Q1 2023 were CNY 261,908,897.81, down from CNY 406,322,679.30 at the end of Q1 2022, representing a decrease of approximately 35.5%[30]. Assets and Liabilities - Total assets at the end of Q1 2023 were CNY 3.74 billion, down 5.30% from the end of the previous year[6]. - Total assets decreased to ¥3,738,068,484.78 in Q1 2023 from ¥3,947,450,797.29 in Q1 2022, reflecting a decline of 5.3%[25]. - Total liabilities decreased by 34.67 million due to repayment of long-term borrowings[19]. - Total liabilities decreased to ¥2,246,130,033.44 in Q1 2023 from ¥2,450,479,523.67 in Q1 2022, a reduction of 8.3%[24]. - Current assets totaled ¥2,755,718,512.10 in Q1 2023, down from ¥2,950,562,653.79 in Q1 2022, a decrease of 6.6%[24]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 25,534[18]. - The largest shareholder, Shanghai Saihai Health Technology Co., Ltd., holds 25,042,470 shares, representing 12.30% of total shares[19]. Strategic Initiatives - The company is undergoing a strategic transformation towards medical intelligence, which has impacted revenue from traditional IVD business[6]. - The company received government grants totaling 364.60 million, contributing positively to other income[19].

Financial Performance - The net profit attributable to shareholders for 2022 was -154,417,230.00 CNY, with cumulative distributable profits amounting to 411,784,160.60 CNY[5] - The parent company reported a net profit of -58,385,751.04 CNY for 2022, with cumulative distributable profits of 314,868,620.89 CNY[5] - The company plans not to distribute cash dividends for the 2022 fiscal year and will not increase capital reserves[5] - The company's revenue for 2022 was approximately CNY 2.31 billion, a decrease of 11.19% compared to CNY 2.60 billion in 2021[23] - The net loss attributable to shareholders for 2022 was CNY 154.42 million, compared to a loss of CNY 49.51 million in 2021[23] - The net cash flow from operating activities was CNY 28.12 million, a significant improvement from a negative cash flow of CNY 133.52 million in 2021[23] - Total assets decreased by 8.06% to CNY 3.95 billion in 2022 from CNY 4.29 billion in 2021[25] - The company reported a significant increase in credit impairment losses due to delayed receivables, amounting to CNY 34.24 million for specific clients undergoing bankruptcy restructuring[26] - The gross profit margin for the IVD segment decreased by 1.49 percentage points to 45.10% in 2022[27] - The basic earnings per share for 2022 was -CNY 0.79, compared to -CNY 0.25 in 2021[30] - The weighted average return on equity was -10.98% in 2022, down from -3.09% in 2021[30] Operational Developments - The company reported a comprehensive range of medical technology services, including centralized procurement and logistics support for medical institutions[12] - The annual report highlighted a focus on molecular diagnostics and point-of-care testing (POCT) technologies, which are critical for enhancing diagnostic accuracy[13] - The company is actively pursuing the establishment of regional inspection centers to support tiered diagnosis and treatment policies, aiming to improve healthcare delivery in local communities[13] - The implementation of a smart supply chain management platform is expected to enhance operational efficiency and reduce costs for medical institutions[14] - The company is committed to achieving CE certification for its products, ensuring compliance with European market standards[13] - The report indicated a strategic emphasis on expanding the company's presence in the medical supply chain sector, particularly in the context of integrated management solutions[14] - The company aims to leverage big data for disease diagnosis and treatment, enhancing its capabilities in healthcare management and reimbursement systems[13] - The annual report noted a focus on research and development of diagnostic reagents and self-built testing methods in laboratories[14] - The company is exploring opportunities for mergers and acquisitions to strengthen its market position and expand its service offerings[12] Strategic Initiatives - The future outlook includes a commitment to enhancing the quality of medical services through innovative technologies and comprehensive management solutions[12] - The company is focusing on a dual business model of "SPD+IVD" to enhance its position as a comprehensive service provider in the smart hospital ecosystem[38] - The strategic plan includes expanding into upstream advanced in vitro diagnostic technologies and outpatient services, aiming to increase market share in the IVD sector[41] - The company aims to enhance customer retention by integrating its own products into existing client systems, thereby increasing revenue and profit continuity[41] - New projects in molecular diagnostics are being introduced to leverage existing resources and improve market share in this area[41] - The company is committed to optimizing its organizational structure and extending its industrial ecosystem to support business development[39] - The company has signed smart medical industry park projects in Chongqing and Liangshan, creating regional SPD project models to capture more market share through localized cooperation[43] - The company aims to build a broad market smart medical ecosystem by leveraging innovative technology, localized services, and channel advantages, responding to the expanding county-level medical market[45] - The company is actively promoting the construction of smart medical digital industry parks to assist in the digital transformation of grassroots medical health services[51] Market Trends and Challenges - The IVD industry in China is experiencing rapid growth due to increasing healthcare spending and an aging population, leading to a sustained demand for medical products and services[54] - The average cost proportion of medical consumables in hospitals with a revenue scale of 1 billion is between 23% and 25%, while hospitals with over 2 billion can reach 33% to 34%[58] - The SPD business is expected to see a continuous increase in demand over the next five years, driven by policy support and the need for refined management in hospitals[62] - The company is positioned as a leading player in the medical consumables market, benefiting from high barriers to entry and a competitive landscape dominated by large enterprises[62] - The company has established regional inspection centers to enhance the quality of medical services, integrating resources to reduce costs and improve testing quality for grassroots medical institutions[64] Governance and Compliance - The company has received a qualified audit opinion from Zhongzheng Zhonghuan Accounting Firm[4] - The board of directors and management have confirmed the accuracy and completeness of the annual report[6] - The company has not provided guarantees in violation of decision-making procedures[7] - The report includes a detailed description of potential risks that the company may face in the future[7] - The company has established a long-term mechanism to prevent fund occupation by controlling shareholders and related parties[140] - The board of directors held 14 meetings during the reporting period, ensuring compliance with governance standards[137] - The company received regulatory warnings from the Shanghai Stock Exchange on July 15, 2022, and was criticized for its management practices, including the actions of its former chairman and general manager[160] - On September 30, 2022, the company was issued a warning letter by the Hubei Securities Regulatory Bureau, which was recorded in the securities market integrity archive[161] - The company was subject to multiple disciplinary actions throughout 2022, including a public reprimand on November 3, 2022, for governance issues involving key executives[162] - In January 2023, the company received an order for rectification from the Hubei Regulatory Bureau, emphasizing the need to improve corporate governance and compliance with regulations[162] Human Resources and Talent Management - The total number of employees in the parent company is 295, while the main subsidiaries employ 1,179, resulting in a total of 1,474 employees[175] - The company has a diverse educational background among employees, with 46 holding postgraduate degrees and 494 having bachelor's degrees[175] - The company emphasizes a competitive and effective compensation policy to motivate employees, linking pay to performance and company results[177] - Training programs are organized to enhance employee skills and core competitiveness, including various training methods such as internal and external training[178] - The company is enhancing its talent acquisition strategy to ensure a supply of skilled professionals to meet the increasing demand in the smart healthcare market[130] Research and Development - The company is prioritizing research and development in innovative healthcare solutions to meet market demands[156] - The company has registered 17 new product certificates during the reporting period, increasing the total to 195[100] - The company is actively pursuing new technology development to improve its diagnostic capabilities[147] - The company is investing $50 million in new product development, focusing on innovative medical technologies[148] Future Outlook - The company plans to expand its market presence by entering three new regions in 2023, aiming for a 15% increase in market share[148] - The company has set a performance guidance for the next fiscal year, projecting a revenue increase of 20%[148] - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market reach[148] - The company plans to recover 1 billion in accounts receivable in 2023, which will significantly alleviate financial pressure and enhance net profit margins[129]